Genocea to drop late-phase herpes drug, cut headcount by Nick Paul Taylor Tuesday, September 26, 2017 The moves refocus Genocea as a player in the hot neoantigen cancer vaccine sector but got short shrift from investors, who drove its stock down 50%.
